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Abstract
Background: B and T cells play a key role in rheumatoid arthritis (RA) pathophysiology. RasGRP1 and RasGRP3 are
involved in T and B cell receptors signaling, and belong to gene combination able to predict infliximab responsiveness,
leading to the question of RasGRP1 and RasGRP3 involvement in RA.
Methods: RasGRP1 and RasGRP3 expression levels were measured by qRT-PCR and/or western-blot in peripheral blood
mononuclear cells (PBMCs), in T and B cells from untreated RA patients and in RA patients treated by TNFα inhibitors. T
and B cells from healthy controls (HC) were cultured with TNFα, and TNFα receptors neutralizing antibodies to
highlight the TNFα effects on RasGRP1 and RasGRP3 pathways. MAPK pathways and apoptosis were respectively
analyzed using the Proteome Profiler arrays and flow cytometry.
Results: In PBMCs from RA patients, gene expression levels of RasGRP1 were invariant while RasGRP3 was
downregulated under TNFα inhibitors and upregulated under TNFα. In T cells from RA patients, RasGRP1 was
decreased and its gene expression level was correlated with disease activity. In T cells from HC, TNFα stimulation
increased RasGRP1 gene expression level while it reduced RasGRP1 protein expression level. Bryostatin-1 experiments
have confirmed that the TNFα effect observed on T cells proliferation was due to the decrease of RasGRP1 expression.
Besides, RasGRP3 expression level increased in PBMCs from RA patients under TNFα and in B cells from HC leading us
to conclude that RasGRP3 in B cells was modulated by TNFα.
Conclusion: This study demonstrates RasGRP1 dysregulation in RA patients while RasGRP3 is characterized as a
biomarker linked to TNFα inhibitors. After binding to TNFR1, TNFα reduced RasGRP1 protein expression resulting in
inhibition of T cell activation.
Trial registration: Clinicaltrials.gov NCT00234234, registered 04 November 2008; NCT00767325, registered 05 October
2005.
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Background
Rheumatoid arthritis (RA) is the most common inflamma-
tory arthritis affecting 1 % of the world population [1]. RA
is characterized by chronic inflammation and proliferation
of the synovial tissue, leading to the destruction of bone
and cartilage. RA is a multifactorial disease involving gen-
etic, environmental and hormonal factors, and immuno-
logical disorders contributing to chronic synovitis [2].
B and T lymphocytes play a central role in RA [3]. Some
abnormalities of antigen receptor signaling pathways in B
and T cells can lead to their dysfunction, particularly by
enhancing the emergence of autoimmunity [4]. The dys-
function of various immune cells is a result of an imbalance
in the production of factors which leads to the overexpres-
sion or conversely, the deletion of other factors, such as
antibodies and cytokines. Among these factors, TNFα has
been identified as a key cytokine in the pathogenesis of RA
maintaining joint inflammation [5, 6]. Indeed, the use of
anti-TNFα drugs has allowed eliciting remission in a high
proportion of RA patients even if 30 % of patients do not
respond to them [7]. Studies have been performed to
highlight predictive biomarkers of response to TNFα in-
hibitors, including RasGRP3 [8]. RasGRP3 has also been
found to be dysregulated in peripheral blood mononuclear
cells (PBMCs) and synovium from RA patients [8, 9]. Fur-
thermore, RasGRP1 has been associated with susceptibil-
ity to RA [10].
RasGRP is a member of the CDC25 family of ras guanyl
nucleotide exchange factors that contain an N-terminal
GEF domain and C-terminal calcium-binding and diacyl-
glycerol (DAG)-binding domains [11]. In mouse, RasGRP3
is expressed in B cells whereas RasGRP1 is highly expressed
in T cells and to a lesser extent in B cells [12–16]. These
proteins are involved in T and B cell receptor (respectively
TCR and BCR) signaling [17, 18]. RasGRP1 also plays a role
in NF-κB pathway inhibition in B cells, leading to their
apoptosis [19]. Ras activation by RasGRP proteins stimu-
lates various effectors systems, leading to changes in gene
expression that are critical for T or B cell development
[20–22]. Indeed, RasGRP1-/- mice become autoimmune-
prone and develop a lupus-like phenotype [20, 22, 23].
These mice displayed an increase of autoreactive CD4+ T
cells, which is the consequence of a lack of positive selec-
tion in the thymus, thus facilitating the activation of B cells
and the production of auto-antibodies (Ab) [12, 13]. In
contrast, RasGRP3-/- mice exhibit hypogammaglobulinemia
and show no sign of autoimmunity [12, 20]. Remarkably,
double mutant mice do not develop signs of autoimmunity
[12]. Therefore, RasGRP1 inhibition promotes autoimmun-
ity via activation of B cells by autoreactive CD4+ T cells,
while RasGRP3 inhibition renders B cells less sensitive to T
cell signals [20].
The identification of RasGRP3 as a biomarker of anti-
TNFα drugs raises the question as to whether RasGRP is
a biomarker related to RA pathology or to the treatment.
We therefore investigated RasGRP1 and RasGRP3 gene
expression in patients treated by two TNFα inhibitors,
adalimumab and etanercept, and in untreated RA pa-
tients compared to healthy controls (HC).
Methods
Subjects
A total of 60 patients (adalimumab (n = 21), etanercept
(n = 9) or abatacept (n = 30)) were included to measure
the impact of biologic agents on RasGRP1 and RasGRP3
expression levels (Additional file 1: Table S1). Patients
treated with adalimumab or etanercept fulfilling the 1987
American College of Rheumatology (ACR) or the 2010
ACR/European League Against Rheumatism (EULAR) cri-
teria for RA were included in the multicenter SATRAPE
study (NCT00234234), approved by the ethics committee
of Upper-Normandy in France (n°2005/006) [24, 25]. RA
patients treated with abatacept, who were used as controls
came from the APPRAISE study (NCT00767325) approved
by the ethics committee of CPP (Comité de Protection des
Personnes) in France [26]. RA patients were treated as rec-
ommended by the manufacturer and the French Drug
Agency ANSM (50 mg every week for etanercept, 40 mg
each other week for adalimumab patients by subcutaneous
injections and 10 mg/kg every month by intravenous injec-
tions for abatacept). Clinical and biological characteristics
such as age, gender, tender and/or swollen joint count, dis-
ease activity score (DAS28), treatments and their dose,
health assessment questionnaire, serum C-reactive protein
level and erythrocyte sedimentation rate, were recorded just
before the first injection and 3 months later.
To compare RasGRP1 and RasGRP3 expression levels
in RA patients and HC, 20 HC (6 male and 14 fe-
male; 32 ± 9 years old) and 32 untreated RA patients
(9 male and 23 female; 53 ± 15 years old) were studied
(Additional file 2: Table S2). At the time when RasGRP1
and RasGRP3 expression levels were measured,
DAS28 was 4.98 ± 1.32. The PBMCs from RA patients
or HC were collected from whole venous blood. All
participants signed an informed consent at the time
of enrollment.
PBMCs were isolated from the buffy-coat of HC to
perform in vitro studies.
Purification of T and B cells
PBMCs were extracted from whole venous blood or
buffy coat using Ficoll-Hypaque (Lymphoprep™, Oslo,
Norway). T and B cells were purified by negative selec-
tion using human T and B cell Dynabeads, respectively,
according to the manufacturer’s instructions (Invitro-
gen™, Carlsbad, CA, USA).
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Lymphocyte cultures
One million PBMCs, T or B cells/well were cultured
into 24-well plates with 1 ml of RPMI 1640 medium
supplemented with 10 % fetal calf serum (FCS), and 0.5 %
penicillin and streptomycin. PBMCs or lymphocytes were
cultured with or without 1 ng/ml of TNFα (R&D Systems,
Minneapolis, MN, USA) and with or without adalimumab
(1 μg/ml), etanercept (10 μg/ml), infliximab (100 μg/ml),
certolizumab (1 μg/ml) or golimumab (100 μg/ml) for 24
or 48 hours in a 5 % CO2 incubator at 37 °C. In neutraliz-
ing experiments, B and T cells were preincubated with
anti-TNF receptor (TNFR)1 (9 μg/ml) or anti-TNFR2
(2.5 μg/ml) (R&D Systems) for 1 hour and TNFα was
added for 48 hours. In activation experiments, T cells were
incubated with IL-2 (60 U/ml) and anti-CD3 antibody
(5 μg/ml) for 4 days. For experiments with Bryostatin-1,
cells were incubated with TNFα for 48 hours. Cells were
then activated with 50 nM Bryostatin-1 (Sigma-Aldrich,
Saint Louis, MO, USA) for 5 hours. Cells were then har-
vested for flow cytometry analysis or RNA and protein
extraction.
Flow cytometry analysis
To control the purity of cell selection, the following anti-
bodies (BD Pharmingen™, Franklin Lakes, NJ, USA) were
used: anti-CD3, anti-CD4, anti-CD8, anti-CD14, anti-
CD19 and anti-CD56. Antibodies used for TNF receptor
expression (anti-TNFR1 and anti-TNFR2) were purchased
from R&D Systems (R&D Systems). To bring out the T
cell activation, the following antibodies (Beckman Coulter,
Brea, CA, USA) were used: anti-CD3, anti-CD25, anti-
HLA-DR. To bring out the early T cell activation, the
marker CD69 was studied after TNFα stimulation by flow
cytometry (BD Pharmingen™). To detect apoptosis in T
cells after TNFα stimulation, a fluorescein isothiocyanate
(FITC) annexin-V Apoptosis Detection Kit (Becton-Dick-
inson, Franklin Lakes, NJ, USA) was used. Appropriate
isotype controls were used in all cases. Acquisition of
samples was performed on a FACSCanto flow cytometer
(Becton-Dickinson), and the data were analyzed with
FlowJo software.
Quantitative measurement of RasGRP1 and RasGRP3
mRNA abundance
RNA samples were obtained using the RNAqueous 4-PCR
kit according to the manufacturer’s instructions (Ambion®,
Austin, TX, USA). cDNA was then synthesized using ran-
dom primers and M-MLV enzyme (Invitrogen™). Quantita-
tive (q)RT-PCR was performed using a Lightcycler as
instructed by the manufacturer (Roche™, Meylan, France).
We chose primers that recognize normal and abnormal
RasGRP1 mRNA. Sequences of primers used for qRT-PCR
were : RasGRP1 forward, 5′-TGCACCGAATTGTCATCT
CC-3′; RasGRP1 reverse, 5′-GTCAATCAGGCGGCAAT
GTA-3′; RasGRP3 forward, 5′-CACGGTCATCAACAAG
CACA-3′; RasGRP3 reverse, 5′-CAGTGTTCGCAGAAG
GTTGG-3′; 18S forward, 5′-GTGGAGCGATTTGTCTG
GTT-3′; 18S reverse, 5′-CGCTGAGCCAGTCAGTGTA
G-3′ (Eurogentec™, Fremont, CA, USA). qRT-PCR reac-
tions for each sample were performed in triplicate using
SYBR-Green and values corrected using control 18S to cali-
brate (Roche™).
Lymphocyte proliferation assay
Cell proliferation is evaluated by incorporation of (3H)-
thymidine. Fifty thousand cells/well of B or T cells in
200 μl of RPMI containing 10 % FCS were seeded into 96-
well plates. Lymphocytes were cultured with or without
TNFα (for 48 and 72 hours) in a 5 % CO2 incubator at
37 °C. After these incubations, 1 μCi of (3H)-thymidine
was added to each well. (3H)-thymidine incorporation was
quantified 16 hours later.
Signaling pathway analysis
A human phospho-kinase Proteome Profiler™ array (R&D
Systems) was used to investigate the mitogen-activated pro-
tein kinase (MAPK) signaling pathways. To conduct this
experiment, B and T cells were rinsed twice with PBS, and
lysis buffer was added. Cell lysates were gently rocked for
30 minutes at 4 °C and then centrifuged at 14,000 g for
5 minutes (4 °C). A total of 200 μg of protein was used for
each array. Human phospho-kinase was purchased from
R&D Systems. Proteins were visualized using a chemilu-
minescence detection system. Arrays were exposed to x-ray
films (5–45 minutes) and developed under standard condi-
tions. The intensity of the immunoreactive bands was
quantified using a blot analysis system (BioRad Laborator-
ies, Hercules, CA, USA).
Immunoblot analysis
B and T cells were incubated with RIPA supplemented
with a protease inhibitor for 30 minutes. Homogenates
were then centrifuged at 16,000 g for 10 minutes at 4 °C.
The protein concentration of supernatant was quantified
using the bicinchoninic acid kit (Pierce Biotechnology,
Rockford, IL, USA). Lysates were suspended in Laemmli
buffer (100 mM Hepes, pH 6.8, 10 % β-mercaptoethanol,
20 % SDS) and boiled for 10 minutes. Proteins (15 to
40 μg) were loaded and resolved on 12 % SDS-PAGE gels.
After electrophoretic separation at 200 V for 1 hour, pro-
teins were transferred to a polyvinylidene difluoride mem-
brane at 30 V for 2 hours. Membranes were then incubated
in a blocking solution (5 % BSA in Tris-buffered saline con-
taining 0.1 % Tween 20) at room temperature for 1 hour
and incubated overnight with one of the following primary
antibodies: mouse anti-human-RasGRP1 (Merck Millipore,
Molsheim, France), mouse anti-human-RasGRP3 (Abcam,
Cambridge, MA, USA), mouse anti-human-extracellular
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signal-regulated kinase (ERK)1/2 (Merck Millipore), mouse
anti-human-phospho-ERK1/2 (Cell Signaling Technology®,
Danvers, MA, USA) or mouse anti-human-glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) (Sigma-Aldrich).
After incubation with the corresponding secondary anti-
bodies coupled to peroxidase (Santa-Cruz Biotechnology,
Santa-Cruz, CA, USA), proteins were visualized using en-
hanced chemiluminescence ECL immunoblotting detection
system (Amersham, UK). Arrays were exposed to x-ray
films (5–20 minutes) and developed under standard condi-
tions. The intensity of the immunoreactive bands was
quantified using a blot analysis system (BioRad Laborator-
ies). Results are reported relative to GAPDH.
Statistical analysis
One-way analysis of variance (ANOVA) followed by
Dunnett post-hoc test was used to compare RasGRP1
and RasGRP3 gene expression levels between different
groups of patients and HC and for the proliferation
assay. One-way ANOVA followed by Bonferroni post-
hoc test was used to compare RasGRP1 and RasGRP3
gene expression levels with or without TNFα and TNFα
inhibitors in HC, and RasGRP1 and RasGRP3 expression
levels with or without TNFα and anti-TNFR treatment.
The nonparametric Wilcoxon paired test was used to com-
pare baseline and post-treatment RasGRP1 and RasGRP3
gene expression levels. Comparison of two populations was
made with Student’s t test. Correlations were assessed using
Pearson’s rank correlation coefficient.
Results
RasGRP3 gene expression level decreased in PBMCs from
RA patients treated by TNFα inhibitors
To better understand the effects of TNFα inhibitors on
RasGRP3, gene expression levels in PBMCs from RA
patients were compared before and after 3 months (V2)
of treatment with an antibody targeting TNFα (adalimu-
mab) or a soluble receptor of TNFα (etanercept), or after
6 months of treatment with abatacept (CTLA4-Ig fusion
protein), another family of biologic agent used in RA as
a control. RasGRP3 gene expression level was signifi-
cantly decreased under adalimumab (p <0.001) or eta-
nercept (p <0.05) after 3 months of treatment
(Fig. 1a). RasGRP is also involved in immune pro-
cesses, but the RasGRP1 gene expression level was
not significantly dysregulated under TNFα inhibitors
Fig. 1 RasGRP1 and RasGRP3 gene expression fluctuations in periperhal blood mononuclear cells (PBMCs) from patients with rheumatoid arthritis
(RA) treated with biologic agents at baseline and after treatment or after in vitro TNFα stimulation. a PBMCs were isolated from whole blood
from RA patients treated with adalimumab (n = 21; 4 male and 17 female; 52 ± 3 years old) and etanercept (n = 9; 4 male and 5 female; 54 ±
5 years old) before treatment (V0) and 3 months later (V2) or abatacept (n = 30; 3 male and 27 female; 61 ± 1 years old) before treatment (V0) and
6 months later (V2). b PBMCs were isolated from whole blood of RA patients untreated with biologics (n = 6; 1 male and 5 female; 54 ± 10 years
old) and cultured with or without TNFα for 24, 48 or 72 hours. Quantitative PCR analysis was performed to measure RasGRP1 and RasGRP3 gene
expression levels. The relative expression levels (in arbitrary units (AU)) of RasGRP1 and RasGRP3 were normalized with 18S RNA abundance. Mean
± standard error of the mean were compared using Student’s t test or the Wilcoxon paired test: *p <0.05; **p <0.01; ***p <0.001
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(Fig. 1a). Otherwise, RasGRP1 (p <0.05) and RasGRP3
(p <0.01) gene expression levels were significantly in-
creased in patients after 6 months of treatment with
abatacept (Fig. 1a).
To highlight the effects of all TNFα inhibitors available
on RasGRP3 gene expression levels in in vitro conditions,
PBMCs from HC were incubated with or without TNFα
and TNFα inhibitors for 1.5, 6.0, 24.0 and 48.0 hours.
TNFα induced a significant increase of RasGRP3 gene
expression levels only after 48.0 hours of stimulation
(Additional file 3) while any modulation was observed at
early time: 1.5, 6.0 and 24.0 hours (data not shown). This
increase of RasGRP3 gene expression level was inhibited
by all TNFα inhibitors (Additional file 3). As expected, no
effect on RasGRP3 gene expression level in PBMCs was
observed when TNFα inhibitors were added to the cul-
tures without TNFα (data not shown). All together, these
results indicate that the decrease of RasGRP3 gene expres-
sion level is specifically associated with all TNFα inhibi-
tors, raising the question about the effects of TNFα on
RasGRP3 expression in RA patients.
RasGRP3 gene expression level increased in PBMCs from
RA patients stimulated by TNFα
To investigate the involvement of TNFα in RasGRP1 and
RasGRP3 gene expression levels in PBMCs from RA pa-
tients, these cells were incubated with or without TNFα for
48 hours. TNFα induced a significant increase of RasGRP3
gene expression level (p <0.05) (Fig. 1b) as observed in
PBMCs from HC (Additional file 3), without an effect on
RasGRP1 gene expression level (Fig. 1b).
RasGRP1 and RasGRP3 were respectively expressed in T
and B cells from HC
While a few studies have described RasGRP1 and
RasGRP3 expression on T and B cells in mice or in cell
lines [12, 21], several studies have only described the
expression of RasGRP1 in T cells [27–30], raising the
question of RasGRP3 expression in human. After nega-
tive selection, the B and T cell purity was 91 % (±0.1 %)
and 96 % (±0.02 %), respectively (Additional file 4). In
HC, RasGRP1 gene expression level was significantly
higher in T cells than in B cells (p <0.01). Conversely,
RasGRP3 gene expression level was significantly higher
in B cells than in T cells (p <0.001) (Fig. 2a). RasGRP1
and RasGRP3 were unexpressed respectively in B and T
cells.
RasGRP1 was dysregulated in T cells from RA patients
RasGRP1 and RasGRP3 gene expression levels were next
measured in T and B cells from RA patients compared
to HC. RasGRP1 gene expression level was significantly
overexpressed in T cells from RA (p <0.01) (Fig. 2b)
while RasGRP3 gene expression level in B cells was not
significantly different between RA patients and HC
(Fig. 2c). To link RasGRP1 or RasGRP3 with RA, we
assessed the correlation between DAS28 and gene ex-
pressions. RasGRP1 gene expression level in T cells was
inversely correlated with the RA disease activity mea-
sured by DAS28 in 24 RA patients (p <0.05) (Fig. 2d).
No correlation between RasGRP3 gene expression level
and DAS28 in B cells was found (data not shown).
To determine whether the increasing of RasGRP1 mRNA
expression level was due to a modification of RasGRP1
function/signaling or if it reflected the activation status of
the T cells, T cells were activated for 4 days with IL-2 and
anti-CD3 antibody. First, we confirmed that T cells activa-
tion markers HLA-DR and CD25 were overexpressed after
4 days of stimulation by flow cytometry (Additional
file 5A). Second, RasGRP1 gene expression level was
significantly increased (p <0.001) after T cell activa-
tion (Additional file 5B).
To confirm these results at the protein level, RasGRP1
and RasGRP3 expression level were measured by western
blot respectively in T and B cells from RA patients
compared to HC. Unexpectedly, the expression of RasGRP1
in T cells from RA patients was 50 % lower (p = 0.05) while
RasGRP3 protein expression level in B cells was not signifi-
cantly different (Fig. 3). Altogether these results indicate
that RasGRP1 is associated with RA disease activity,
whereas RasGRP3 was not involved in RA pathophysiology.
Surprisingly, the gene and protein RasGRP1 expression
changed in the opposite sense in RA patients.
TNFα influences RasGRP1 and RasGRP3 gene expression
levels respectively in T and B cells
In RA, TNFα is a key pro-inflammatory cytokine in-
volved in RA pathophysiology and is also a thera-
peutic target. To better understand the involvement
of TNFα on RasGRP1 and RasGRP3 gene expression
levels on T and B cells, respectively, these cells from
buffy coats were incubated with or without TNFα for 24
or 48 hours. TNFα induced an increase of RasGRP1 (p
<0.001) and RasGRP3 (p <0.01) gene expression levels
after 48 hours of stimulation (Fig. 4a). To further investi-
gate the potential role of TNFR1 and/or TNFR2 in TNFα-
induced increase of RasGRP1 or RasGRP3 gene expres-
sion levels, we studied the effects of two antibodies
neutralizing TNFR1 and TNFR2 specifically. First, we
confirmed that TNFR1 and TNFR2 were expressed in B
and T cells by flow cytometry (Fig. 4b). Second, the
TNFR1 and TNFR2 neutralizing antibodies inhibited the
TNFα-induced increase of RasGRP1 (p <0.001) and
RasGRP3 (p <0.05) gene expression levels in T and B cells
respectively (Fig. 4c). No effect was observed when T
or B cells were treated only with TNFR1 or TNFR2
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Fig. 3 RasGRP1 and RasGRP3 protein expression levels in T and B cells in healthy controls (HC) and rheumatoid arthritis (RA) patients. Western
blot analysis was performed to measure RasGRP1 and RasGRP3 protein expression in T and B cells, respectively. RasGRP1 protein expression was
measured in T cells from HC (n = 4) and RA patients (n = 5). RasGRP3 protein expression was measured in B cells from HC (n = 4) and RA patients
(n = 3). A value of 1 was arbitrarily assigned to control conditions to which glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was reported
and expressed as fold change. Mean ± standard error of the mean were compared using Student’s t test
Fig. 2 RasGRP1 and RasGRP3 gene expression levels in B and T cells from healthy controls and patients with rheumatoid arthritis (RA). After T and
B cell negative selection, quantitative PCR analysis of RasGRP1 and RasGRP3 gene expression was performed. a RasGRP1 and RasGRP3 gene
expression levels in B and T cells from healthy controls (HC) (n = 20; 6 male and 14 female; 32 ± 9 years old). b RasGRP1 and c RasGRP3 gene
expression levels respectively in T and B cells from HC (n = 20; 6 male and 14 female; 32 ± 9 years old) and patients with RA (n = 26; 8 male and
18 female; 53 ± 15 years old). d Correlation between RasGRP1 gene expression level in T cells and RA disease activity (disease activity score in 28
joints (DAS28)) was assessed using Pearson’s rank correlation coefficient. The relative expression levels (in arbitrary units (AU)) of RasGRP1 and
RasGRP3 were normalized with 18S RNA abundance. Mean ± standard error of the mean were compared using the Wilcoxon paired test or one-
way analysis of variance followed by Dunnett post-hoc test. * p < 0.05; ** p < 0.01; *** p < 0.001
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neutralizing antibodies (Additional file 6). No syner-
gistic effect on RasGRP1 and RasGRP3 gene expres-
sion levels was observed when both TNFR1 and
TNFR2 antibodies were simultaneously added to the
cultures (data not shown). These experiments showed
that TNFα modifies RasGRP1 or RasGRP3 expression
via TNFR1 or TNFR2.
TNFα influences RasGRP1 and RasGRP3 protein
expression levels respectively in T and B cells
In T cells, TNFα induced a significant decrease of
RasGRP1 protein expression level after 48 hours of
stimulation (p <0.05). As previously demonstrated in T
cells from RA patients, the RasGRP1 gene (Fig. 4a) and
protein (Fig. 5a) expressions changed in the opposite
sense under TNFα stimulation. The use of TNFR1
neutralizing antibodies with TNFα had no effect on
RasGRP1 expression while TNFR2 neutralizing anti-
bodies with TNFα decrease RasGRP1 expression sug-
gesting the participation of TNFR1 for RasGRP1
expression (Fig. 5a). In B cells, TNFα induced an in-
crease of RasGRP3 protein expression level after
48 hours of stimulation (p <0.05) (Fig. 5b) but TNFα
had no effect on RasGRP3 protein expression level after
previous neutralization of TNFR1 or TNFR2 (Fig. 5b).
Overall, TNFα increased the RasGRP1 gene expression
level while it decreased RasGRP1 protein expression
independently of TNFR2. On the contrary, TNFα in-
creased RasGRP3 mRNA and protein expression levels
via TNFR1 or TNFR2.
Functional effects of TNFα on T and B cells
RasGRP1 and RasGRP3 are involved respectively in TCR
and BCR signaling pathways. TNFα modulates RasGRP1
and RasGRP3 in Tand B cells, respectively. To date, no link
between TNFR1 or TNFR2 and RasGRP1 or RasGRP3 has
been described in the literature. Therefore, we character-
ized the TNFα effects in upstream and downstream of
RasGRP1 and RasGRP3 on TCR and BCR signaling path-
ways. First, we evaluated cell proliferation under TNFα by
(3H) thymidine incorporation. After 72 hours of stimula-
tion, TNFα reduced proliferation only on T cells (p <0.05)
(Fig. 6a) without apoptosis increasing (Additional file 7).
To better understand the decrease of T cell prolifera-
tion induced by TNFα and the putative link between
RasGRP1 and TNFR1, a human phospho-kinase array
kit was used to measure Lyn, Lck, phospholipase-Cγ1
(PLCγ1) (upstream of RasGRP), MEK, ERK and RSK
Fig. 4 TNFα influences RasGRP1 and RasGRP3 gene expression levels in T and B cells respectively via TNFR1 and TNFR2. a Quantitative PCR analysis was
performed to measure RasGRP1 and RasGRP3 gene expression levels in T and B cells, respectively, obtained from three buffy coats. In each condition, cells
were cultured with or without TNFα for 24 and 48 hours. b TNF receptor (TNFR)1 and TNFR2 expression in B (CD19) and T cells (CD3) was checked by flow
cytometry. c Quantitative PCR analysis was performed to measure RasGRP1 and RasGRP3 gene expression levels in T and B cells, respectively, from three
buffy coats. In each condition, T or B cells, previously exposed to anti-TNFR1 or anti-TNFR2 neutralizing antibodies, were cultured with TNFα for 48 hours.
The relative expression levels (in arbitrary units (AU)) of RasGRP1 and RasGRP3 were normalized with 18S RNA abundance. Mean ± standard error of the
mean were compared using one-way analysis of variance followed by Bonferroni post-hoc test: *p <0.05; **p <0.01; ***p <0.001
Golinski et al. Arthritis Research & Therapy  (2015) 17:382 Page 7 of 12
(downstream of RasGRP) phosphorylation after 48 hours
of TNFα stimulation. Indeed, the antigen binding to TCR
or BCR, co-localized respectively with Lck and Lyn, in-
duced RasGRP activation via the PLCγ1 [17, 18, 22]. The
RasGRP proteins activate the small GTPase Ras resulting in
the activation of the MAPK cascade Ras-Raf-MEK-
ERK-RSK [18, 31]. TNFα induced significant inhibition
of Lck, ERK and RSK phosphorylation (p <0.05) in T
cells while TNFα had no significant effect on protein
pathway phosphorylations in B cells (Fig. 6b). To con-
firm that TNFα inhibits ERK phosphorylation, T cells
were incubated with or without TNFα and TNFR1 and
TNFR2 neutralizing antibodies. TNFα induced a signifi-
cant decrease of ERK phosphorylation after 48 hours of
stimulation (p <0.05) (Fig. 6c). Whereas the use of
TNFR1 neutralizing antibodies seems to inhibit the
TNFα-induced decrease of ERK phosphorylation, the
use of TNFR2 neutralizing antibodies had no effect on
TNFα action (Fig. 6c). These results confirm the results
obtained with RasGRP1 shown in Fig. 5a. So, TNFα
induced a significant decrease of RasGRP1 protein ex-
pression level after 48 hours of stimulation, followed by
an inhibition of ERK phosphorylation and T cell prolifer-
ation (Fig. 6). To confirm that inhibition of ERK phos-
phorylation and T cell proliferation is due to the decrease
of RasGRP1 expression, T cells were stimulated with
Bryostatin-1 (an activator of RasGRP1) for 5 hours after
TNFα incubation. CD69 expression (a marker of T cell
activation) was measured by flow cytometry. Bryostatin-1
induced CD69 expression in human T cells (Fig. 6d, left
and middle panels). However, TNFα inhibited the in-
crease of CD69 expression induced by Bryostatin-1 (74 %
versus 58 %) (Fig. 6d, right panel). In conclusion, TNFα
binding to TNFR1 inhibits RasGRP1 expression, followed
by inhibition of ERK phosphorylation and subsequent
decrease in T cell proliferation.
Discussion
Previous studies conducted in our laboratory have iden-
tified RasGRP3 as a biomarker of TNFα inhibitor (inflix-
imab) response and RA synovial tissue [8, 9]. These
observations and the literature analysis lead us to won-
der whether RasGRP family proteins have a role in RA.
As RasGRP2 and RasGRP4 are expressed respectively in
neuronal cells and mast cells [13, 21], we focused our
study on RasGRP1 and RasGRP3 expression involved
respectively in TCR and BCR signaling.
We demonstrated the preferential expression of RasGRP1
and RasGRP3 mRNAs, respectively, in human T and B
cells. The other data available on RasGRP1 and RasGRP3
are derived from experimental studies in mice, from cell
lines and from systemic lupus erythematosus (SLE) T cells
[12, 20]. These experiments showed that in mice RasGRP1
is expressed in B and T cells whereas RasGRP3 is expressed
only in B cells. Therefore, our results in humans are in ac-
cordance with the experimental data on the expression
levels of these proteins in lymphocytes from mice. In
addition, in Jurkat T-cell-lines, RasGRP1 maintains expres-
sion of TCRα mRNA and surface expression of the TCR/
CD3 complex suggesting a regulatory function of RasGRP1
signal in peripheral T cells [32]. A subset of SLE patients
have defective expression of RasGRP1 because of aberrant
splicing. To rule out the hypothesis that the modulation of
RasGRP1 transcript level is due to different isoforms of
RasGRP1 identified by Yasuda et al. [29], we measured the
expression level of the different isoforms present in RNA
Fig. 5 TNFα influences RasGRP1 and RasGRP3 protein expression levels respectively in T and B cells via TNF receptor (TNFR)1 and TNFR2. Western
blot analysis was performed to measure RasGRP1 protein expression in T cells from five healthy controls (HC) (a) and RasGRP3 protein expression
in B cells from three HC (b). In the control condition, cells were cultured without TNFα treatment. Cells were cultured with TNFα for 48 hours and
with or without antibodies targeting TNFR1 or TNFR2. A value of 1 was arbitrarily assigned to control conditions (without TNFα treatment) to
which glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was reported and expressed as fold change. Mean ± standard error of the mean
were compared using one-way analysis of variance followed by the Dunnett post-hoc test: *p <0.05; **p <0.01
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samples from 18 RA patients. We found no substantial
difference in the levels of the normal, full-length RasGRP1
transcript in these cells relative to that of the cells from HC
(data not shown). Moreover, the primers chosen for
RasGRP1 qRT-PCR were located upstream of exon 11, the
exon preferentially deleted in SLE patients and determined
by Yasuda et al. [29].
In our study, the analysis of RasGRP1 and RasGRP3
expression levels showed only upregulation of RasGRP1 in
T cells from RA patients compared to HC (Fig. 2b).
Recent genome-wide association studies have identified
RasGRP1 as a gene of susceptibility in RA [10], which sup-
ports the dysregulation of RasGRP1 in RA. Moreover,
RasGRP1 gene expression was also correlated with RA
disease activity (Fig. 2d) as was observed in SLE [33]. But
RasGRP1 and disease activity were inversely correlated in
RA while they were positively correlated in SLE suggesting
different ways of regulation in these two diseases. Further-
more, in T cells from RA patients compared with those of
HC, RasGRP1 gene expression level was increased in T
cells (Fig. 2b) while RasGRP1 protein expression was re-
duced (Fig. 3). However, T cell activation experiments
showed that the activation status of these cells sharply
increases the RasGRP1 gene expression level (Additional
file 5B). So, the increased RasGRP1 gene expression level
observed in RA patients could reflect the T cell activation
status occurring in this inflammatory context. Moreover,
these opposing observations could be explained by the
presence of microRNA-21 targeting RasGRP1 mRNA.
However, microRNA-21 was previously highlighted as be-
ing overexpressed in SLE and RA patients [34, 35].
In vitro studies with T cells from HC showed us that
TNFα stimulation (a key cytokine in RA pathophysi-
ology) increased RasGRP1 gene expression level (Fig. 4a)
while it reduced RasGRP1 protein expression level
(Fig. 5a). This discrepancy could be explained by the
presence of microRNA-21. Indeed, several studies have
demonstrated that microRNA-21 could be upregulated
Fig. 6 Functional effects of TNFα in B and T cells. a Cell proliferation was evaluated with (3H) thymidine incorporation by B and T cells with or without
TNFα (n = 3). b Analysis of mitogen-activated protein kinase (MAPK) phosphorylation in B and T cells with or without TNFα for 48 hours was performed
with a human phospho-kinase array kit to measure Lyn, Lck, PLCγ1, MEK, ERK and RSK phosphorylation (n = 2). The dotted line represents the control
condition without TNFα. c Western blot analysis was performed to measure ERK1/2 and phospho-ERK1/2 protein expressions in T cells from five
healthy controls (HC). Cells were cultured with or without TNFα for 48 hours and with or without antibodies targeting TNFR1 or TNFR2. Histogram
represents ratio of phosphorylated ERK1/2 to total ERK. A value of 1 was arbitrarily assigned to control conditions (without TNFα treatment) to which
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) was reported and expressed as fold change. d After incubation with 1 ng/ml of TNFα for 48 hours,
cells were stimulated with 50nM Bryostatin-1 for 5 hours. CD69 expression in T cells (CD3) was assessed using flow cytometry (one representative result of
three independent experiments is presented). Mean ± standard error of the mean were compared using Student’s t test or one-way analysis of variance
followed by Dunnett post-hoc test. *p <0.05; **p <0.01
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by TNFα in cancer or in some inflammatory pathology
[36–39]. These data are in agreement with the results
found in the RasGRP1-/- mouse model, in which mice
became autoimmune-prone and developed a lupus-like
phenotype [20]. Indeed, this study demonstrated that
RasGRP1 inhibition instigates the emergence of auto-
immunity. However, TNFα did not induce modulation of
RasGRP1 gene expression level in PBMCs from RA pa-
tients (Fig. 1a). The hypothesis would be that the
addition of TNFα in vitro to PBMCs from RA patients,
already in an inflammatory environment, has no effect on
RasGRP1 gene expression level. This phenomenon is even
more reinforced by the absence of an effect of TNFα in-
hibitors on RasGRP1 gene expression level (Fig. 1a).
Whereas the use of TNFR1 neutralizing antibody inhib-
ited the TNFα-induced decreasing of RasGRP1 expression
level, the use of TNFR2 neutralizing antibody had no ef-
fect on TNFα action (Fig. 5a). These results could be
explained by the fact that the TNFR1 binds soluble TNFα,
whereas TNFR2 binds only the membrane TNFα. In ac-
cordance with these results, we demonstrated inhibition
of T cell proliferation (Fig. 6a) and also significant inhib-
ition of Lck, ERK and RSK phosphorylation after TNFα
treatment (Fig. 6b). We also demonstrated that TNFα
inhibited ERK phosphorylation and only the use of
TNFR1 neutralizing antibody inhibited this TNFα effect
(Fig. 6c). Moreover, bryostatin-1 experiments have con-
firmed that the TNFα effect observed in T cell prolifera-
tion and ERK phosphorylation was indeed due to the
decrease of RasGRP1 expression (Fig. 6d).
To better understand RasGRP3 function, we measured
RasGRP1 and RasGRP3 gene expression levels in pa-
tients treated by adalimumab and etanercept (TNFα in-
hibitors), and abatacept, a CTLA4-Ig fusion protein as
control. RasGRP3 mRNA abundance was decreased only
in PBMCs from RA patients treated by TNFα inhibitors
but was increased in PBMCs from RA patients treated
with abatacept. Furthermore, RasGRP3 gene expression
levels were not correlated with DAS28 score (data not
shown) and RasGRP3 was not dysregulated in RA pa-
tients compared to HC (Figs. 2c and 3b). On the con-
trary, RasGRP3 gene expression level increased two-fold
in PBMCs from RA patients (Fig. 1b) and six-fold in B
cells from HC after 48 hours of culture with TNFα
(Figs. 4a and 5b), leading us to conclude that RasGRP3
in B cells was modulated by TNFα. So, it is not surpris-
ing to find RasGRP3 as a biomarker of responsiveness to
TNFα inhibitors [8]. TNFα induced RasGRP3 increase
via TNFR1 and TNFR2. These results are in accordance
with the effects of TNFα inhibitors on RasGRP3 gene
expression level. Indeed, patients treated by TNFα inhib-
itors display a decrease of RasGRP3 gene expression
level. So, the inhibition of RasGRP3 gene expression
seems to be of good prognosis for RA patients. In
addition, double mutant mice RasGRP1-/- RasGRP3-/- do
not develop signs of autoimmunity contrary to
RasGRP1-/- mice [12]. Therefore, RasGRP3 is a bio-
marker related to TNFα inhibitors.
Aberrant splicing and expression of RasGRP4 were
discovered respectively in PBMCs and in the fibroblast-
like synoviocytes (FLS) of a subset of RA patients [40, 41].
The defective transcripts led to alteration of the MAPK
pathway in PBMCs while the level of RasGRP4 transcript
was correlated with the FLS proliferation rate [40, 41].
Any aberrant splicing of RasGRP1 or RasGRP3 was found
in our RA patients (data not shown). In experimental
arthritis, RasGRP4-null mice did not develop K/BxN in-
flammatory arthritis and intra-articular injection of
RasGRP4-specific siRNAs reduced the severity of the dis-
ease, suggesting that RasGRP4 is a potential target of ther-
apy in RA [41]. Moreover, RasGRPs represent potential
therapeutic targets in cancer [42]. Taken together, the
study on RasGRP4 and our study focused on RasGRP1
and RasGRP3 bring new insights into a regulatory func-
tion of the RasGRP protein family in FLS and/or in im-
mune cells from RA patients, thereby representing a
potential target in RA.
Conclusion
In summary, our study demonstrated the dysregulation of
RasGRP1 in RA patients and the role of RasGRP3 as a bio-
marker of adalimumab and etanercept. This study suggests
a link in T and B cells, never described previously, between
RasGRP1 or RasGRP3 and TNFα. While the response to
TNFα inhibitors in RA patients modulates RasGRP3 gene
expression, TNFα inhibits RasGRP1 protein expression,
leading to TCR pathway inhibition. We can speculate the
establishment of a negative feedback by TNFα to inhibit T
cell activation, via RasGRP1 inhibition (Additional file 8).
Taken together, the recent study on RasGRP4 and these
new data focused on RasGRP1 and RasGRP3 bring new
insights into a regulatory function of the RasGRP protein
family in FLS and/or in immune cells from RA patients,
thereby representing a potential target in RA.
Additional files
Additional file 1: Table S1. Clinical and biological characteristics of
rheumatoid arthritis (RA) patients treated with adalimumab, etanercept or
abatacept. (DOC 61 kb)
Additional file 2: Table S2. Clinical features of patients and healthy
controls. (DOC 40 kb)
Additional file 3: Modulation of RasGRP3 gene expression levels in
peripheral blood mononuclear cells (PBMCs) from healthy controls
(HC) incubated with TNFα and adalimumab, etanercept, infliximab,
certolizumab or golimumab. Quantitative PCR analysis was performed
to measure RasGRP3 gene expression levels in PBMCs obtained from HC
treated by TNFα and TNFα inhibitors. In each condition, cells were
cultured with or without TNFα for 48 hours and adalimumab (n = 4) (a),
etanercept (n = 3) (b), infliximab (n = 3) (c), certolizumab (n = 3) (d) or
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golimumab (n = 3) (e) was added. The relative expression levels (in
arbitrary units (AU)) of RasGRP3 were normalized with 18S RNA
abundance. Mean ± standard error of the mean were compared using
one-way analysis of variance followed by Bonferroni post-hoc test:
*p <0.05; **p <0.01; ***p <0.001. (TIF 1307 kb)
Additional file 4: T and B cell purity. After negative selection of
peripheral blood mononuclear cells from healthy controls, buffy coat and
rheumatoid arthritis patients, cytometric analysis of T and B cell purity
was checked. a Cytometric analysis of human T cell purity with CD3, CD4
and CD8 labeling. b Cytometric analysis of human B cell purity with
CD19 labeling. (TIF 1096 kb)
Additional file 5: T cell activation induces an increase of RasGRP1
gene expression level. After T cell negative selection, cells were
cultured with IL-2 and anti-CD3 antibody for 4 days (n = 3). a To evaluate
the T cell activation status, HLA-DR and CD25 expressions in T cells (CD3)
was checked by flow cytometry. b quantitative PCR analysis of RasGRP1
gene expression was performed. The relative expression levels (in arbitrary
units (AU)) of RasGRP1 were normalized with 18S RNA abundance.
Mean ± standard error of the mean were compared using Student’s
t test: ***p <0.001. (TIF 100 kb)
Additional file 6: TNF receptor (TNFR)1 and TNFR2 have no effect
on RasGRP1 and RasGRP3 gene expression level in T and B cells
respectively. Quantitative PCR analysis was performed to measure
RasGRP1 and RasGRP3 gene expression levels in T and B cells respectively
from three healthy controls. T or B cells were exposed to anti-TNFR1 or
anti-TNFR2 neutralizing antibodies without TNFα for 48 hours. The relative
expression levels (in arbitrary units (AU)) of RasGRP1 and RasGRP3 were
normalized with 18S RNA abundance. Mean ± standard error of the
mean were compared using one-way analysis of variance followed by
Bonferroni post-hoc test. (TIF 47 kb)
Additional file 7: TNFα has no effect on T cell apoptosis. After T cell
negative selection, cells were cultured with or without TNFα for 48 and
72 hours. To measure apoptosis, a fluorescein isothiocyanate (FITC)
annexin-V Apoptosis Detection Kit (BD Biosciences, USA) was used.
After labeling with FITC annexin-V and propidium iodide (PI), cells were
analyzed by flow cytometry within 1 hour. a One representative result of
three independent experiments is presented. b Histogram represents the
mean ± standard error of the mean (SEM) of percentage of annexin-V
positive cells in three independent experiments. Mean ± SEM were
compared using Student’s t test. (TIF 1318 kb)
Additional file 8: A model of RasGRP1 regulation by TNFα. In T
cells, TNFα binding to TNF receptor-1 (TNFR1) leads to a decrease of
RasGRP1 protein expression after 48 hours of stimulation. This
mechanism prevents mitogen-activated protein kinase activation and
induces inhibition of T cell activation and proliferation. We can speculate
the establishment of a negative feedback by TNFα to inhibit T cell
activation after 48 hours of stimulation, via RasGRP1 inhibition.
(TIF 869 kb)
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